In developing this automated cell therapy processing platform, Limula’s founders aim to create a disruptive production ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

Dr. Radhakrishnan brings significant experience in product development and commercialization that will be particularly valuable as Candel prepares for its Biologics License Application (BLA) ...

Shares of the biotech Kymera Therapeutics are up 50% since Monday, when data from an early trial hinted that its pill might ...

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ...

A dual-track approach has gained momentum for biotech companies as capital markets remain volatile and acquirers become more ...

For people diagnosed with macular telangiectasia type 2 (MacTel)—a rare and slowly progressing retinal disease—there have ...

The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA ...

TAO price holds steady around $410–$420 in June 2025 as Bittensor expands AI subnets and gains institutional support.

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

The CDMO's head of development talks about ADCs, accelerated timelines, and the push for end-to-end development services.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.